Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CVKD
#4448
Cadrenal Therapeutics, Inc. - Common Stock
4.9
6
USD
+1.22%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.22%
Monthly Change
-9.32%
6 month change
-10.14%
Year Change
-10.14%
Previous Close
4.9
0
Open
4.9
7
Low
4.9
1
High
5.0
2
Volume
9
Markets
US Stock Market
Healthcare
CVKD
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
775.64 K
5 M
1.88 M
2.51 M
2.87 M
Valuation ratios
Enterprise value
—
2.22 M
17.24 M
12.99 M
13.04 M
Price to earnings ratio
—
-1.07
-1.66
-1.02
-0.96
Price to sales ratio
—
-12.1
—
—
—
Price to cash flow ratio
—
-2.54
-2.4
-1.07
-1.02
Price to book ratio
—
1.16
2.38
4.94
0.95
Enterprise value to EBITDA ratio
—
-0.26
-1.57
—
—
Profitability ratios
Return on assets %
-0.01
-0.98
-1.05
-3.06
-0.87
Return on equity %
0
-1.09
-1.43
-4.83
-1.39
Return on invested capital %
—
-37 K
-148.21 K
-733.48 K
—
Gross margin %
—
129.74
—
—
—
Operating margin %
—
1 031.27
—
—
—
EBITDA margin %
—
1 157.07
—
—
—
Net margin %
—
1 129.12
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
0.55
10.27
3.77
2.72
2.68
Inventory turnover
—
—
—
—
—
Asset turnover
—
-0.16
0
—
—
Solvency ratios
Debt to assets ratio
1.48
0
—
—
—
Debt to equity ratio
-0.21
0
—
—
—
Long term debt to total assets ratio
-0.14
-0.09
—
—
—
Long term debt to total equity ratio
0.02
-0.1
—
—
—
Per share metrics
Operating cash flow per share
—
-3.92
-6.03
-6.32
-5.23
EBIT per share
—
-9.55
-8.99
—
—
EBITDA per share
—
-9.52
-8.99
—
—
Total debt per share
—
0
—
—
—
Cash per share
—
9.34
8.2
2.01
0.96
Net current asset value per share
—
9.44
8.29
2.17
1.19
Tangible book value per share
—
8.55
6.1
1.37
0.75
Working capital per share
—
8.52
6.09
1.37
0.74
Book value per share
—
8.55
6.1
1.37
0.75
News
Cadrenal schedules FDA meeting for HIT drug CAD-1005
Cadrenal Therapeutics stock surges on Phase 2 trial results
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc.
Cadrenal therapeutics CFO Szot sells $1496 in shares
Szot, CFO of Cadrenal, sells $174k in CVKD stock
Cadrenal therapeutics (CVKD) CEO Pham sells $131,779 in stock
Cadrenal Therapeutics acquires eXIthera’s anticoagulant portfolio